Companies › Olatec Therapeutics
1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Neurology, Immunology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dapansutrile NACHT, LRR and PYD domains-containing protein 3 inhibitor | NLRP3 | Phase 2 | Acute Gout Flare; Parkinson Disease; Diabetes Mellitus, Type 2; Melanoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05658575 | Dapansutrile | Phase 2 | Acute Gout Flare | Immunology | Dec 2026 |
| NCT04971499 | Dapansutrile | Phase 1 | Melanoma | Oncology | Apr 2027 |
| NCT07157735 | Dapansutrile | Phase 2 | Parkinson Disease | Neurology | May 2027 |
| NCT06047262 | Dapansutrile | Phase 2 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Jul 2028 |
Shenzhen Wingor Biotechnology NeuroBiogen Corxel Pharmaceuticals Shanghai Jiaolian Drug Research and Development Urovant Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.